Phases, active trials: Phase 1: 5, Phase 2: 13, Phase 2/3: 4, Phase 3: 12, Phase 4: 1, No phase listed: 7
argenx has built one of the most productive clinical platforms in autoimmune disease through its ABDEG technology, engineered antibodies that enhance FcRn-mediated IgG catabolism, reducing pathogenic autoantibody levels. Efgartigimod (Vyvgart, Vyvdura) is the lead asset: a first-in-class FcRn antagonist approved in generalized myasthenia gravis (gMG), primary immune thrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and pemphigus vulgaris. Efgartigimod's mechanism, reducing all IgG subclasses including pathogenic autoantibodies, positions it as a platform therapy across any antibody-mediated autoimmune disease. argenx is systematically expanding efgartigimod into additional indications including thyroid eye disease, Sjögren's disease, multifocal motor neuropathy (MMN), spinal muscular atrophy (SMA), and Lambert-Eaton myasthenic syndrome (LEMS). Empasiprubart (ARGX-117), targeting complement C2, represents the company's second platform, entering Phase 3 in MMN and other complement-mediated diseases.
- Neuromuscular disease (myasthenia gravis, CIDP, MMN, LEMS)
- Autoimmune disease (ITP, pemphigus, thyroid eye disease, Sjögren's)
- FcRn-mediated IgG reduction (efgartigimod platform)
- Complement inhibition (empasiprubart, C2 targeting)
- Rare pediatric diseases (SMA, congenital myasthenic syndrome)
- Neonatal medicine (antibody-mediated neonatal disease)
- Efgartigimod (Vyvgart IV / Vyvdura SC): FcRn antagonist, gMG/ITP/CIDP/pemphigus
- Efgartigimod subcutaneous: next-gen delivery, multiple indications
- Empasiprubart (ARGX-117): anti-C2 complement inhibitor, MMN and others
- ARGX-119: anti-C2, neuromuscular (earlier-stage)
- ARGX-118: IgE-FcRn modulator (allergic disease)
- ARGX-220: antibody-mediated rejection
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20… NCT04812925 | Primary completion moved at least 12 months later Primary endpoint(s) modified | Active, Not Recruiting |
3 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With… NCT06284954 | Nov 2026 · Estimated | Phase 2 |
3 more on the Completions page. See the calendar →
Monitor the argenx pipeline daily
Get a daily digest when argenx registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Generalized Myasthenia Gravis | 6 |
| gMG | 6 |
| Myasthenia Gravis | 5 |
| AChR-Ab Seropositive Generalized Myasthenia Gravis | 3 |
| CIDP | 3 |
| Congenital Myasthenic Syndrome | 3 |
| Generalized Myasthenia Gravis (gMG) | 3 |
| Multifocal Motor Neuropathy (MMN) | 3 |
argenx is registering new efgartigimod trials across autoimmune conditions on a near-monthly basis, each new indication registration represents a potential $1B+ market opportunity. Their trial data in CIDP (which showed unprecedented response rates) has set the bar for future FcRn inhibitor approvals. Competitors (UCB's rozanolixizumab, Johnson & Johnson's nipocalimab) are tracking argenx's trial expansions closely.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to argenx's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: argenx may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your argenx pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630 | Recruiting | Trial sites expanded: 89 → 94 locations | 2026-11-10 |
| A Natural History Study in Participants With Congenital Myasthenic Syndromes… NCT06078553 | Active, Not Recruiting | Study completion pushed from Jun 2027 to Sep 2027 | 2026-11-06 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and… NCT07673627 | Recruiting | Trial sites expanded: 8 → 14 locations | 2026-11-05 |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults… NCT06920004 | Recruiting | Trial sites expanded: 101 → 107 locations | 2026-11-04 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult… NCT07570316 | Recruiting | Trial sites expanded: 32 → 35 locations | 2026-11-04 |
Each trial page shows every change DataLookout has recorded for that trial.